EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon‐Like Peptide‐1 Receptor Agonists in Type 2 Diabetes

Mohamed H Eldesouki iD, Omar Alkasabrah, Mohammed Kloub, Hazem Abosheaishaa iD, Khaled Elfert iD, Arpit Sharma iD, Sherif Andrawes, Nikki Duong

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70238 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Mohamed H Eldesouki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Gallstones, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely prescribed for type 2 diabetes mellitus (T2DM) because of their benefits in glycemic control, weight reduction, and cardiovascular outcomes. This study evaluated the risk of gallbladder disease among diabetic patients treated with GLP‐1 RAs.

Methods

A retrospective cohort analysis was performed using the TriNetX research network. Adults ≥ 18 years with T2DM who received GLP‐1 RAs were identified and compared with matched controls. Propensity score matching (1:1) was used to balance baseline characteristics. Outcomes included cholelithiasis/choledocholithiasis, cholecystitis, pancreatitis, endoscopic retrograde cholangiopancreatography (ERCP), and cholecystectomy. Subgroup analyses were performed according to GLP‐1 RA agents.

Results

A total of 156,376 patients were included; 43,077 patients were in the GLP‐1 RA cohort and 113,299 patients were in the control group. After matching, 39,140 patients remained in each group. At two years, patients with GLP‐1 RA use had higher rates of cholelithiasis/choledocholithiasis (aOR 1.44, 95% CI 1.24–1.65), whereas rates of cholecystectomy were non‐significant. By three years, GLP‐1 RA use remained associated with higher rates of cholelithiasis/choledocholithiasis (aOR 1.43, 95% CI 1.24–1.63), cholecystitis (aOR 1.45, 95% CI 1.14–1.83), and cholecystectomy (aOR 1.54, 95% CI 1.17–2.02). There were no significant differences in the rates of pancreatitis or ERCP. Semaglutide and dulaglutide demonstrated higher cholelithiasis, whereas liraglutide and exenatide were not associated with a significant increase.

Conclusion

GLP‐1 RAs use in patients with T2DM was associated with modestly higher rates of cholelithiasis/choledocholithiasis, cholecystitis, and cholecystectomy, whereas there were no significant differences in rates of pancreatitis or ERCP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2GallstonesGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsAgedFemaleHumansMaleMiddle AgedCholangiopancreatography, Endoscopic RetrogradeCholecystectomyCholecystitisCholedocholithiasisCholelithiasisExenatideGlucagon-Like PeptidesImmunoglobulin Fc FragmentsPancreatitisRetrospective StudiesSemaglutideRecombinant Fusion Proteins

Stichwörter der Autor:innen

biliary complicationscholedocholithiasischolelithiasisgallbladder diseaseglucagon‐like peptide‐1 receptor agoniststype 2 diabetes mellitus

Substanzen

dulaglutideExenatideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsSemaglutideRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA.
  • Department of Internal Medicine, New York Medical College/Landmark Medical Center, Woonsocket, Rhode Island, USA.
  • Division of Gastroenterology and Hepatology, Brooklyn Health Center, Brooklyn, New York, USA.
  • Division of Gastroenterology and Hepatology, West Virginia University School of Medicine, Morgantown, West Virginia, USA.
  • Faculty of Medicine, Monash University/Monash Health, Victoria, Melbourne, Australia.
  • Division of Gastroenterology and Hepatology, Staten Island University Hospital-Northwell Health, Staten Island, New York, USA.

ORCID-Profile: Mohamed H Eldesouki, Hazem Abosheaishaa, Khaled Elfert, Arpit Sharma

Zitieren

APA

Eldesouki, M. H., Alkasabrah, O., Kloub, M., Abosheaishaa, H., Elfert, K., Sharma, A., Andrawes, S., & Duong, N. (2026). Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon‐Like Peptide‐1 Receptor Agonists in Type 2 Diabetes. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70238

Vancouver

Eldesouki MH, Alkasabrah O, Kloub M, Abosheaishaa H, Elfert K, Sharma A, et al. Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon‐Like Peptide‐1 Receptor Agonists in Type 2 Diabetes. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70238

BibTeX
@article{Eldesouki2026,
  author = {Eldesouki, Mohamed H and Alkasabrah, Omar and Kloub, Mohammed and Abosheaishaa, Hazem and Elfert, Khaled and Sharma, Arpit and Andrawes, Sherif and Duong, Nikki},
  title = {Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon‐Like Peptide‐1 Receptor Agonists in Type 2 Diabetes},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70238}
}
Kostenlos starten →